SGMT insider transaction filings
Sagimet Biosciences Inc. — 40 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-17. Screen SGMT transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-17 | 4 | Kemble George — Director | Option exercise (M): 326,618 @ $6.36 · Option exercise (M): 24,369 @ $6.36 · Sale (S): 350,987 @ $10.23 · Option exercise (M): 326,618 (derivative) @ $0 · Option exercise (M): 24,369 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Kemble George — Director | Option exercise (M): 9,751 @ $6.36 · Option exercise (M): 10,455 @ $6.36 · Sale (S): 20,206 @ $9.95 · Option exercise (M): 9,751 (derivative) @ $0 · Option exercise (M): 10,455 (derivative) @ $0 | EDGAR |
| 2026-07-22 | 4 | Happel David — President & CEO, Director | Sale (S): 64,051 @ $7.76 | EDGAR |
| 2026-07-22 | 4 | Rozek Elizabeth — Chief Legal & Admin. Officer | Sale (S): 10,545 @ $7.76 | EDGAR |
| 2026-07-22 | 4 | Kemble George — Director | Sale (S): 18,844 @ $7.46 | EDGAR |
| 2026-06-15 | 4 | Hoelscher Paul W. — Director | Grant/award (A): 39,567 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Jarrett Jennifer — Director | Grant/award (A): 39,567 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Kemble George — Director | Grant/award (A): 39,567 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Phillips Anne M. — Director | Grant/award (A): 39,567 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | GRAMMER ELIZABETH A — Director | Grant/award (A): 39,567 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | SEIDENBERG BETH C — Director | Grant/award (A): 39,567 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Chauche Thierry — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Grauer Andreas — Chief Medical Officer | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Rozek Elizabeth — Chief Legal & Admin. Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Happel David — President & CEO, Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Grauer Andreas — Chief Medical Officer | Grant/award (A): 264,759 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Rozek Elizabeth — Chief Legal & Admin. Officer | Grant/award (A): 44,000 @ $0 · Grant/award (A): 88,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Martins Eduardo Bruno — Chief Medical Officer | Grant/award (A): 44,000 @ $0 · Grant/award (A): 88,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Happel David — President & CEO, Director | Grant/award (A): 128,000 @ $0 · Grant/award (A): 256,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Chauche Thierry — Chief Financial Officer | Grant/award (A): 44,000 @ $0 · Grant/award (A): 88,000 (derivative) @ $0 | EDGAR |
| 2026-02-12 | 4 | Happel David — President & CEO, Director | Sale (S): 12,101 @ $5.36 | EDGAR |
| 2026-02-12 | 4 | Chauche Thierry — Chief Financial Officer | Sale (S): 1,312 @ $5.36 | EDGAR |
| 2026-02-12 | 4 | Martins Eduardo Bruno — Chief Medical Officer | Sale (S): 3,640 @ $5.36 | EDGAR |
| 2026-02-12 | 4 | Rozek Elizabeth — Chief Legal & Admin. Officer | Sale (S): 2,622 @ $5.36 | EDGAR |
| 2025-11-21 | 4 | Kemble George — Executive Chairman, Director | Sale (S): 37,688 @ $7.69 | EDGAR |
| 2025-11-06 | 4 | Rozek Elizabeth — Chief Legal & Admin. Officer | Grant/award (A): 9,855 @ $0 · Grant/award (A): 13,367 (derivative) @ $0 | EDGAR |
| 2025-07-23 | 4 | Happel David — President & CEO, Director | Sale (S): 65,478 @ $9.13 | EDGAR |
| 2025-07-23 | 4 | Martins Eduardo Bruno — Chief Medical Officer | Sale (S): 8,277 @ $9.13 | EDGAR |
| 2025-07-23 | 4 | Rozek Elizabeth — General Counsel and CCO | Sale (S): 10,780 @ $9.13 | EDGAR |
| 2025-06-10 | 4 | Phillips Anne M. — Director | Grant/award (A): 27,268 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Kemble George — Director | Grant/award (A): 32,250 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Jarrett Jennifer — Director | Grant/award (A): 27,268 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Hoelscher Paul W. — Director | Grant/award (A): 32,250 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Walbert Timothy P — Director | Grant/award (A): 32,250 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | GRAMMER ELIZABETH A — Director | Grant/award (A): 32,250 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | SEIDENBERG BETH C — Director | Grant/award (A): 28,522 (derivative) @ $0 · Grant/award (A): 32,250 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Martins Eduardo Bruno — Chief Medical Officer | Grant/award (A): 34,000 @ $0 · Grant/award (A): 138,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Happel David — President & CEO, Director | Grant/award (A): 116,000 @ $0 · Grant/award (A): 472,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Rozek Elizabeth — General Counsel and CCO | Grant/award (A): 34,000 @ $0 · Grant/award (A): 138,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Chauche Thierry — Chief Financial Officer | Grant/award (A): 17,000 @ $0 · Grant/award (A): 69,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Sagimet Biosciences Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-21 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-27 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-27 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SGMT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →